)
Visual
test
Silence Therapeutics
Silence Therapeutics (SLN) investor relations material
Silence Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Mar, 2026
Executive summary
Achieved expedited enrollment in Phase 2 SANRECO trial for divesiran in polycythemia vera, with topline results now expected in Q3 2026, earlier than previously anticipated.
Completed Phase 3 readiness for zerlasiran, positioning it for potential partnership and further development in cardiovascular disease.
AstraZeneca will not pursue SLN312 beyond Phase 1; Silence regains global rights and is evaluating next steps.
Advanced preclinical pipeline with promising data for SLN365 (cholesterol management) and SLN098 (obesity).
Leadership changes include appointment of interim CEO and new board members.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $85.1 million as of December 31, 2025.
Collaboration revenue dropped to $0.6 million in 2025 from $43.3 million in 2024, mainly due to concluded Hansoh collaboration and reduced AstraZeneca revenue.
R&D expenses were $67.8 million in 2025, nearly flat year-over-year.
G&A expenses decreased to $22.3 million in 2025 from $26.9 million in 2024, reflecting cost-saving initiatives.
Net loss widened to $88.6 million ($0.63 per share) in 2025 from $45.3 million ($0.33 per share) in 2024.
Outlook and guidance
Topline results for divesiran Phase 2 SANRECO trial expected in Q3 2026.
Additional preclinical data for SLN365 and SLN098 anticipated in Q2 2026.
Phase 1 data presentations for SLN312 planned for 2026 medical congresses.
Plans for SLN312 after AstraZeneca exit
Zerlasiran Phase 3 partnership strategy
Status of extra-hepatic cell targeting research
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Silence Therapeutics
- Divesiran eliminated phlebotomy need and maintained hematocrit control with strong safety.SLN
Study Result3 Feb 2026 - Lead siRNA programs show strong efficacy and durability, advancing toward late-stage trials.SLNMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Lead siRNA therapies show strong efficacy and safety, with pivotal data and trials ahead.SLNH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Lead siRNA therapies show high efficacy and safety, advancing toward pivotal trials and partnerships.SLN2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Multiple siRNA programs show strong clinical progress, with robust data and a solid financial runway.SLNChardan Genetic Medicines Conference20 Jan 2026
- siRNA programs show high efficacy in Lp(a) and PV, with phase 3 trials and strong partnerships ahead.SLNJefferies London Healthcare Conference 202413 Jan 2026
- Zerlasiran achieves >90% Lp(a) knockdown; PV program shows strong efficacy; phase 3 plans advance.SLNPiper Sandler 36th Annual Healthcare Conference11 Jan 2026
- Cash runway extended to 2027 as revenue grows and key siRNA programs advance.SLNQ4 202426 Dec 2025
- Advancing siRNA therapies with strong clinical data, global support, and financial stability.SLNLeerink’s Global Healthcare Conference 202517 Dec 2025
Next Silence Therapeutics earnings date
Q1 20267 May, 2026
Silence Therapeutics
Next Silence Therapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage